How to take advantage of incentives to develop your orphan products in Europe ?
extract of webinar orphan drugs
May 6, 2022
  • Drug Development

As you want to start regulatory interactions in Europe for an orphan drug, you may face many challenges or miss game changing opportunities.


Indeed, the European Medicines Agency (EMA) provides specific incentives to companies who are granted ODD for their product as well as additional financial advantage to companies registered as SME (special status).


During this process you may face challenges especially if you are not familiar with the EU health authorities, EU accelerated pathways or existing incentives. Also if you have very limited or no resources/expertise in Europe and that you need to focus Regulatory Affairs Team on development activities.


Our experts will help you to understand how to optimize the development of your orphan products in Europe »


Learning objectives :


  • What are the key numbers and key figures in orphan drug development?
  • What is the regulatory context for Orphan Medicinal products in EU?
  • What are the benefits of collaborating with European regulatory experts? »

Access the Full Webinar and the slide deck

    By sending this form, I agree that my personal data will be saved and processed according to data protection regulations and will be used only for commercial and marketing purposes only.

    Learn more

    BlueReg undertakes to comply with the regulations in force applicable to the processing of personal data and, in particular, Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 applicable as from 25 May 2018 (hereinafter, "the General Data Protection Regulations" or GPDR) and the national laws resulting therefrom.
    Any inquiries, correction or declaration of event related to personal data processed should be sent to: GDPR data request

    GDPR data request

    Thank you! You can watch the webinar now.

    Download your document